Cover Image
Market Research Report

Bacillary Dysentery (Shigellosis) - Pipeline Review, H1 2019

Published by Global Markets Direct Product code 383706
Published Content info 54 Pages
Delivery time: 1-2 business days
Price
Back to Top
Bacillary Dysentery (Shigellosis) - Pipeline Review, H1 2019
Published: March 18, 2019 Content info: 54 Pages
Description

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Bacillary Dysentery (Shigellosis) - Pipeline Review, H1 2019, provides an overview of the Bacillary Dysentery (Shigellosis) (Infectious Disease) pipeline landscape.

Shigella Infections (Shigellosis) is an intestinal disease caused by bacteria known as shigella. Symptoms include diarrhea, abdominal cramps and fever. Predisposing factors include eating contaminated food, age, international travelers and homosexual men. Treatment includes antibiotics.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Bacillary Dysentery (Shigellosis) - Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Bacillary Dysentery (Shigellosis) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Bacillary Dysentery (Shigellosis) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Bacillary Dysentery (Shigellosis) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 1, 6 and 2 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 3, 2 and 2 molecules, respectively.

Bacillary Dysentery (Shigellosis) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Bacillary Dysentery (Shigellosis) (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Bacillary Dysentery (Shigellosis) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Bacillary Dysentery (Shigellosis) (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Bacillary Dysentery (Shigellosis) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Bacillary Dysentery (Shigellosis) (Infectious Disease)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Bacillary Dysentery (Shigellosis) (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Bacillary Dysentery (Shigellosis) (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Product Code: GMDHC11141IDB

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Bacillary Dysentery (Shigellosis) - Overview
    • Bacillary Dysentery (Shigellosis) - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Bacillary Dysentery (Shigellosis) - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Bacillary Dysentery (Shigellosis) - Companies Involved in Therapeutics Development
    • Akthelia Pharmaceuticals Ltd
    • Chongqing Zhifei Biological Products Co Ltd
    • GlaxoSmithKline Plc
    • Immuron Ltd
    • Polyneuron Pharmaceuticals AG
    • Protein Potential LLC
  • Bacillary Dysentery (Shigellosis) - Drug Profiles
    • (shigella + typhoid) (Bivalent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AKT-10081 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GSK-3536852A - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GVXNSD-133 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IMM-124E - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • infectious disease vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PN-109 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SC-599 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SF2a-TT15 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • shigella (bivalent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • shigella [serotype 2a] vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • shigella [strain 53G] vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • shigella vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • shigella vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • shigella vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • shigella vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Shigetec - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Activate IL-10 for Bacterial Infections and Crohn's Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Bacillary Dysentery (Shigellosis) - Dormant Projects
  • Bacillary Dysentery (Shigellosis) - Product Development Milestones
    • Featured News & Press Releases
      • Jul 29, 2013: GlycoVaxyn Secures CHF 5.1 Million Strategic Translation Award From the Wellcome Trust to Finance Clinical Development of Shigella Vaccine
      • Jan 27, 2012: IVI Granted Two U.S. Patents On Dysentery Vaccine Inventions
      • Oct 08, 2010: GlycoVaxyn Phase I Clinical Study Shows Positive Data With Shigella Dysenteriae Vaccine Candidate Against Severe Diarrheal Disease
      • Feb 23, 2010: GlycoVaxyn Initiates Phase I Clinical Study with Bioconjugate Vaccine
      • Feb 15, 2007: IVI Scientists Develop New Laboratory Animal Model For Shigella
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Bacillary Dysentery (Shigellosis), H1 2019
  • Number of Products under Development by Companies, H1 2019
  • Number of Products under Development by Universities/Institutes, H1 2019
  • Products under Development by Companies, H1 2019
  • Products under Development by Universities/Institutes, H1 2019
  • Number of Products by Stage and Target, H1 2019
  • Number of Products by Stage and Mechanism of Action, H1 2019
  • Number of Products by Stage and Route of Administration, H1 2019
  • Number of Products by Stage and Molecule Type, H1 2019
  • Bacillary Dysentery (Shigellosis) - Pipeline by Akthelia Pharmaceuticals Ltd, H1 2019
  • Bacillary Dysentery (Shigellosis) - Pipeline by Chongqing Zhifei Biological Products Co Ltd, H1 2019
  • Bacillary Dysentery (Shigellosis) - Pipeline by GlaxoSmithKline Plc, H1 2019
  • Bacillary Dysentery (Shigellosis) - Pipeline by Immuron Ltd, H1 2019
  • Bacillary Dysentery (Shigellosis) - Pipeline by Polyneuron Pharmaceuticals AG, H1 2019
  • Bacillary Dysentery (Shigellosis) - Pipeline by Protein Potential LLC, H1 2019
  • Bacillary Dysentery (Shigellosis) - Dormant Projects, H1 2019

List of Figures

  • Number of Products under Development for Bacillary Dysentery (Shigellosis), H1 2019
  • Number of Products under Development by Companies, H1 2019
  • Number of Products under Development by Universities/Institutes, H1 2019
  • Number of Products by Targets, H1 2019
  • Number of Products by Stage and Targets, H1 2019
  • Number of Products by Mechanism of Actions, H1 2019
  • Number of Products by Stage and Mechanism of Actions, H1 2019
  • Number of Products by Routes of Administration, H1 2019
  • Number of Products by Stage and Routes of Administration, H1 2019
  • Number of Products by Molecule Types, H1 2019
  • Number of Products by Stage and Molecule Types, H1 2019
Back to Top